lifirafenib Tag

Shots: The agreement involves assessing safety, efficacy and tolerability of BeiGene's RAFi dimer, lifirafenib (BGB-283) and SpringWorks' MEKi (PD-0325901), in patients with advanced solid tumours BeiGene will look forward for onset of P-Ib trial for advanced solid tumours while SpringWorks will oversee fixed dosing formulation in trial The P-Ib trial is expected to initiate in Q1’19 while the costing and governance responsibilities of the trial will be...

Read More